Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

× No keyword cloud information.

21 in total

1. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Authors: Hans J Hammers; Henk M Verheul; Brenda Salumbides; Rajni Sharma; Michelle Rudek; Janneke Jaspers; Preeti Shah; Leigh Ellis; Li Shen; Silvia Paesante; Karl Dykema; Kyle Furge; Bin T Teh; George Netto; Roberto Pili
Journal: Mol Cancer Ther Date: 2010-05-25 Impact factor: 6.261

2. Molecular characterization of head and neck cancer: how close to personalized targeted therapy?

Authors: Maria J Worsham; Haythem Ali; Jadranka Dragovic; Vanessa P Schweitzer
Journal: Mol Diagn Ther Date: 2012-08-01 Impact factor: 4.074

Review 3. Regional treatment strategies for in-transit melanoma metastasis.

Authors: Ryan S Turley; Amanda K Raymond; Douglas S Tyler
Journal: Surg Oncol Clin N Am Date: 2011-01 Impact factor: 3.495

Review 4. Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors: Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal: Expert Opin Drug Metab Toxicol Date: 2011-10-07 Impact factor: 4.481

Review 5. Emerging drugs to treat squamous cell carcinomas of the head and neck.

Authors: Christopher Fung; Jennifer R Grandis
Journal: Expert Opin Emerg Drugs Date: 2010-09 Impact factor: 4.191

6. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors: Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal: Blood Date: 2008-09-29 Impact factor: 22.113

7. Anti-angiogenesis therapies: their potential in cancer management.

Authors: Andrew Eichholz; Shairoz Merchant; Andrew M Gaya
Journal: Onco Targets Ther Date: 2010-06-24 Impact factor: 4.147

8. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.

Authors: Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Michael Ihnat; Satyendra Shenoy; Roy L Kisliuk
Journal: J Med Chem Date: 2010-02-25 Impact factor: 7.446

9. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment.

Authors: Mark Warren; Peter M Venner; Scott North; Tina Cheng; Chris Venner; Sunita Ghosh; Allison A Venner; Daygen Finch
Journal: Can Urol Assoc J Date: 2009-08 Impact factor: 1.862

10. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.

Authors: Teresa Diago; Jose S Pulido; Julian R Molina; Lucienne C Collett; Thomas P Link; Edwin H Ryan
Journal: Mayo Clin Proc Date: 2008-02 Impact factor: 7.616